Mursla (Cambridge, UK) is an emergent techbio startup, leveraging extracellular vesicle biology to deliver nextgen multi-omics liquid biopsy tests.

Its first product is a blood test to significantly improve the early detection of liver cancer among high-risk populations so that more patients can benefit from curative treatments (surgery/transplant).

Its test is first-in-class and is differentiated from first generation liquid biopsy blood tests using circulating free DNA since it is tissue-specific, multi-omics and offers real time snapshot of disease biology.

Mursla was selected as UK Life Sciences Innovator 2023 in the Diagnostics and Precision Medicine category.